EVENITY™ is indicated for the treatment of osteoporosis in postmenopausal women at high risk for fracture, defined as a history of osteoporotic fracture, or multiple risk factors for fracture; or patients who have failed or are intolerant to other available osteoporosis therapy. Read More

available osteoporosis therapy. The anabolic effect of EVENITY™ wanes after 12 monthly doses of therapy. Therefore, the duration of EVENITY™ use should be limited to 12 monthly doses. If osteoporosis therapy remains warranted, continued therapy with an antiresorptive agent should be considered. Close
For the treatment of postmenopausal women
with osteoporosis at high risk for fracture

EVENITY™ works differently with a dual effect1-3

Simultaneously increases bone formation while reducing resorption to a lesser extent1

US women over the age of 50 will have an osteoporosis-related fracture in her lifetime4

Women with postmenopausal osteoporosis are 5 times more likely to suffer another fracture within a year5

Now there is a treatment that simultaneously increases bone formation while reducing resorption to a lesser extent1

Now there is a treatment that simultaneously increases bone formation while reducing resorption to a lesser extent1

Start EVENITY™ after an osteoporosis-related fracture1

Nearly 12,000 women with postmenopausal osteoporosis were studied in three phase 3 trials1,6

EVENITY™ is the only bone builder administered monthly for 12 doses1,3,7

EVENITY™ should be administered via subcutaneous injection by a healthcare provider1

Patients should be adequately supplemented with calcium and vitamin D during treatment with EVENITY™1

Osteoporosis-related fractures can significantly impact the lives of postmenopausal women8

Questions about coverage and support for EVENITY™?

Find ordering, coding, and billing information as well as personalized support services for you and your patients throughout the claims process


EVENITY™ may increase the risk of myocardial infarction, stroke and cardiovascular death. EVENITY™ should not be initiated in patients who have had a myocardial infarction or stroke within the preceding year. Consider whether the benefits outweigh the risks in patients with other cardiovascular risk factors. Monitor for signs and symptoms of myocardial infarction and stroke and instruct patients to seek prompt medical attention if symptoms occur. If a patient experiences a myocardial infarction or stroke during therapy, EVENITY™ should be discontinued.

References: 1. EVENITY™ (romosozumab-aqqg) prescribing information, Amgen. 2. Pavone V, Testa G, Giardina, C, Vescio A, Restivo D, Sessa G. Pharmacological therapy of osteoporosis: A systematic current review of literature. Front Pharmacol. 2017;8:803. 3. Tymlos® (abaloparatide) prescribing information, Radius Health, Inc. 4. US Department of Health and Human Services. Bone Health and Osteoporosis: A Report of the Surgeon General. Rockville, MD: Department of Health and Human Services, Office of the Surgeon General; 2004. 5. van Geel TA, van Helden S, Geusens PP, Winkens B, Dinant GJ. Clinical subsequent fractures cluster in time after first fractures. Ann Rheum Dis. 2009;68:99-102. 6. Langdahl BL, Libanati C, Crittenden DB, et al. Romosozumab (sclerostin monoclonal antibody) versus teriparatide in postmenopausal women with osteoporosis transitioning from oral bisphosphonate therapy: a randomised, open-label, phase 3 trial. Lancet. 2017;390:1585-1594. 7. Forteo® (teriparatide) prescribing information, Eli Lilly and Company. 8. Cosman F, de Beur SJ, LeBoff MS, et al. Clinician’s guide to prevention and treatment of osteoporosis. Osteoporos Int. 2014;25:2359-2381.